B effector cells in rheumatoid arthritis and experimental arthritis

References

• Franklin EC, Holman HR, Muller-Eberhard HJ, . An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957; 105 5: 425–438.
   Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001; 40 2: 205–211.
   PubMed Web of Science ®Google Scholar
• Wardemann H, Yurasov S, Schaefer A, . Predominant autoantibody production by early human B cell precursors. Science. 2003; 301 5638: 1374–1377.
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Crosbie J, Adelstein S, . Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988; 334 6184: 676–682.
   Google Scholar
• Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 1989; 337 6207: 562–566.
   Google Scholar
• Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med. 1993; 177 4: 1009–1020.
   Google Scholar
• Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med. 1994; 179 1: 125–134.
   Google Scholar
• Samuels J, Ng YS, Coupillaud C, . Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005; 201 10: 1659–1667.
   PubMed Web of Science ®Google Scholar
• Yurasov S, Wardemann H, Hammersen J, . Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005; 201 5: 703–711.
   PubMed Web of Science ®Google Scholar
• Wang H, Clarke SH. Evidence for a ligand-mediated positive selection signal in differentiation to a mature B cell. J Immunol. 2003; 171 12: 6381–6388.
   Google Scholar
• Wang LD, Lopes J, Cooper AB, . Selection of B lymphocytes in the periphery is determined by the functional capacity of the B cell antigen receptor. Proc Natl Acad Sci USA. 2004; 101 4: 1027–1032.
   Google Scholar
• Yurasov S, Tiller T, Tsuiji M, . Persistent expression of autoantibodies in SLE patients in remission. J Exp Med. 2006; 203 10: 2255–2261.
   PubMed Web of Science ®Google Scholar
• Menard L, Samuels J, Ng YS, . Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum. 2011; 63 5: 1237–1245.
   Google Scholar
• McLean AR, Rosado MM, Agenes F, . Resource competition as a mechanism for B cell homeostasis. Proc Natl Acad Sci USA. 1997; 94 11: 5792–5797.
   Google Scholar
• De Boer RJ, Freitas AA, Perelson AS. Resource competition determines selection of B cell repertoires. J Theor Biol. 2001; 212 3: 333–343.
   Google Scholar
• Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature. 1994; 371 6496: 389–395.
   Google Scholar
• Schiemann B, Gommerman JL, Vora K, . An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001; 293 5537: 2111–2114.
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, . BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285 5425: 260–263.
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, . BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999; 189 11: 1747–1756.
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, . Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999; 190 11: 1697–1710.
   PubMed Web of Science ®Google Scholar
• Thompson JS, Bixler SA, Qian F, . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001; 293 5537: 2108–2111.
   PubMed Web of Science ®Google Scholar
• Rahman ZS, Rao SP, Kalled SL, . Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med. 2003; 198 8: 1157–1169.
   PubMed Web of Science ®Google Scholar
• Lesley R, Xu Y, Kalled SL, . Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004; 20 4: 441–453.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20 6: 785–798.
   PubMed Web of Science ®Google Scholar
• Seyler TM, Park YW, Takemura S, . BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005; 115 11: 3083–3092.
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, . BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005; 1050:34–39.
   PubMed Web of Science ®Google Scholar
• Moura RA, Cascao R, Perpetuo I, . Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford). 2011; 50 2: 278–282.
   Google Scholar
• Gottenberg JE, Miceli-Richard C, Ducot B, . Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther. 2009; 11 4: R114.
   Web of Science ®Google Scholar
• Moura RA, Weinmann P, Pereira PA, . Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford). 2010; 49 6: 1082–1092.
   Google Scholar
• Souto-Carneiro MM, Mahadevan V, Takada K, . Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009; 11 3: R84.
   PubMed Web of Science ®Google Scholar
• Cambridge G, Stohl W, Leandro MJ, . Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006; 54 3: 723–732.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I, . Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006; 8 6: R167.
   PubMedGoogle Scholar
• Nakajima K, Itoh K, Nagatani K, . Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol. 2007; 36 5: 365–372.
   PubMed Web of Science ®Google Scholar
• Masson-Bessiere C, Sebbag M, Durieux JJ, . In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 2000; 119 3: 544–552.
   Google Scholar
• Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol. 2009; 21 3: 205–210.
   Google Scholar
• Vidard L, Kovacsovics-Bankowski M, Kraeft SK, . Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol. 1996; 156 8: 2809–2818.
   Google Scholar
• Lanzavecchia A, Bove S, Specific B. lymphocytes efficiently pick up, process and present antigen to T cells. Behring Inst Mitt. 198577: 82–87.
   Google Scholar
• Abbas AK, Haber S, Rock KL. Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. J Immunol. 1985; 135 3: 1661–1667.
   PubMed Web of Science ®Google Scholar
• Hamel K, Doodes P, Cao Y, . Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+T cell reactivity. J Immunol. 2008; 180 7: 4994–5003.
   Google Scholar
• Bouaziz JD, Yanaba K, Venturi GM, . Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in mice. Proc Natl Acad Sci USA. 2007; 104 52: 20878–20883.
   Google Scholar
• van de Veerdonk FL, Lauwerys B, Marijnissen RJ, . The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011; 63 6: 1507–1516.
   PubMedGoogle Scholar
• O'Neill SK, Shlomchik MJ, Glant TT, . Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol. 2005; 174 6: 3781–3788.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ, Takemura S, . Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res. 2000; 2 6: 457–463.
   PubMedGoogle Scholar
• Monach PA, Hueber W, Kessler B, . A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci USA. 2009; 106 37: 15867–15872.
   Google Scholar
• Jenkins MK, Taylor PS, Norton SD, . CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991; 147 8: 2461–2466.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Grosmaire L, . Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173 3: 721–730.
   Google Scholar
• Azuma M, Ito D, Yagita H, . B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993; 366 6450: 76–79.
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994; 265 5176: 1225–1227.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Sperling AI, Cooke MP, . Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol. 1994; 153 5: 1990–1997.
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Akalin E, Chandraker A, . CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995; 155 10: 4521–4524.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, . CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174 3: 561–569.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev. 2009; 229 1: 307–321.
   PubMed Web of Science ®Google Scholar
• Valle A, Aubry JP, Durand I, . IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int Immunol. 1991; 3 3: 229–235.
   Google Scholar
• Constant S, Schweitzer N, West J, . B lymphocytes can be competent antigen-presenting cells for priming CD4+T cells to protein antigens in vivo. J Immunol. 1995; 155 8: 3734–3741.
   Google Scholar
• Stack RM, Lenschow DJ, Gray GS, . IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol. 1994; 152 12: 5723–5733.
   Google Scholar
• Tellander AC, Pettersson U, Runstrom A, . Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease. J Autoimmun. 2001; 17 1: 39–50.
   Google Scholar
• Iwai H, Kozono Y, Hirose S, . Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol. 2002; 169 8: 4332–4339.
   Google Scholar
• Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol. 1996; 26 10: 2320–2328.
   PubMed Web of Science ®Google Scholar
• O'Neill SK, Cao Y, Hamel KM, . Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol. 2007; 179 8: 5109–5116.
   Google Scholar
• Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol. 1991; 146 6: 1722–1729.
   Google Scholar
• Yellin MJ, Sinning J, Covey LR, . T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol. 1994; 153 2: 666–674.
   PubMed Web of Science ®Google Scholar
• Lumsden JM, Williams JA, Hodes RJ. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J Immunol. 2003; 170 2: 781–787.
   Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005; 23:515–548.
   PubMed Web of Science ®Google Scholar
• Schroder AE, Greiner A, Seyfert C, . Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 1996; 93 1: 221–225.
   PubMed Web of Science ®Google Scholar
• Takemura S, Braun A, Crowson C, . Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001; 167 2: 1072–1080.
   PubMed Web of Science ®Google Scholar
• Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006; 6 3: 205–217.
   PubMed Web of Science ®Google Scholar
• Manzo A, Paoletti S, Carulli M, . Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol. 2005; 35 5: 1347–1359.
   PubMed Web of Science ®Google Scholar
• Page G, Miossec P. Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol. 2004; 204 1: 28–38.
   Google Scholar
• Gregorio A, Gambini C, Gerloni V, . Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford). 2007; 46 2: 308–313.
   PubMed Web of Science ®Google Scholar
• Timmer TC, Baltus B, Vondenhoff M, . Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum. 2007; 56 8: 2492–2502.
   Google Scholar
• Luther SA, Lopez T, Bai W, . BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity. 2000; 12 5: 471–481.
   PubMed Web of Science ®Google Scholar
• Wengner AM, Hopken UE, Petrow PK, . CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum. 2007; 56 10: 3271–3283.
   Google Scholar
• Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. J Immunol. 2004; 172 6: 3422–3427.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Ravikumar R, Barnard J, . Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008; 180 2: 688–692.
   PubMed Web of Science ®Google Scholar
• Canete JD, Celis R, Moll C, . Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009; 68 5: 751–756.
   Web of Science ®Google Scholar
• Manser T. Textbook germinal centers?. J Immunol. 2004; 172 6: 3369–3375.
   Google Scholar
• Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol. 2002; 20:165–196.
   PubMed Web of Science ®Google Scholar
• Gause A, Gundlach K, Zdichavsky M, . The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Eur J Immunol. 1995; 25 10: 2775–2782.
   Google Scholar
• Humby F, Bombardieri M, Manzo A, . Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009; 6 1: e1.
   PubMed Web of Science ®Google Scholar
• Rosengren S, Wei N, Kalunian KC, . Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther. 2008; 10 5: R105.
   Google Scholar
• Kim HJ, Krenn V, Steinhauser G, . Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol. 1999; 162 5: 3053–3062.
   PubMed Web of Science ®Google Scholar
• Aarvak T, Natvig JB. Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res. 2001; 3 1: 13–17.
   Google Scholar
• Takemura S, Klimiuk PA, Braun A, . T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001; 167 8: 4710–4718.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Rosengren S, Lee SJ, . Assessment of rituximab's immunomodulatory synovial effects (ARISE trial) 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008; 67 3: 402–408.
   PubMed Web of Science ®Google Scholar
• Teng YK, Levarht EW, Toes RE, . Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis. 2009; 68 6: 1011–1016.
   PubMed Web of Science ®Google Scholar
• Buch MH, Boyle DL, Rosengren S, . Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009; 68 7: 1220–1227.
   PubMed Web of Science ®Google Scholar
• Catalan D, Aravena O, Sabugo F, . B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010; 12 2: R68.
   PubMed Web of Science ®Google Scholar
• Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol. 2010; 10 4: 236–247.
   PubMed Web of Science ®Google Scholar
• Harris DP, Haynes L, Sayles PC, . Reciprocal regulation of polarized cytokine production by effector B and T cells. Nature Immunol. 2000; 1:475–481.
   PubMed Web of Science ®Google Scholar
• Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today. 1997; 18 7: 343–350.
   Google Scholar
• Yeo L, Toellner KM, Salmon M, . Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis. 2011; 70 11: 2022–2028.
   PubMed Web of Science ®Google Scholar
• Keystone E, Emery P, Peterfy CG, . Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009; 68 2: 216–221.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, . B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002; 3 10: 944–950.
   PubMed Web of Science ®Google Scholar
• Mauri C, Gray D, Mushtaq N, . Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003; 197 4: 489–501.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Takedatsu H, . Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002; 16 2: 219–230.
   PubMed Web of Science ®Google Scholar
• Evans JG, Chavez-Rueda KA, Eddaoudi A, . Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007; 178 12: 7868–7878.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Haas KM, . A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008; 28 5: 639–650.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsushita T, . The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol. 2009; 182 12: 7459–7472.
   PubMed Web of Science ®Google Scholar
• Blair PA, Norena LY, Flores-Borja F, . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32 1: 129–140.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, . Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011; 117 2: 530–541.
   PubMed Web of Science ®Google Scholar
• Rantapaa-Dahlqvist S, de Jong BA, Berglin E, . Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48 10: 2741–2749.
   PubMedGoogle Scholar
• Hueber W, Kidd BA, Tomooka BH, . Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2005; 52 9: 2645–2655.
   PubMed Web of Science ®Google Scholar
• Kouskoff V, Korganow AS, Duchatelle V, . Organ-specific disease provoked by systemic autoimmunity. Cell. 1996; 87 5: 811–822.
   PubMed Web of Science ®Google Scholar
• Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med. 1983; 158 2: 378–392.
   PubMed Web of Science ®Google Scholar
• Ji H, Ohmura K, Mahmood U, . Arthritis critically dependent on innate immune system players. Immunity. 2002; 16 2: 157–168.
   PubMed Web of Science ®Google Scholar
• Hietala MA, Jonsson IM, Tarkowski A, . Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol. 2002; 169 1: 454–459.
   Google Scholar
• Kaplan CD, O'Neill SK, Koreny T, . Development of Inflammation in Proteoglycan-Induced Arthritis Is Dependent on FcgammaR Regulation of the Cytokine/Chemokine Environment. J Immunol. 2002; 169 10: 5851–5859.
   Google Scholar
• Kaplan CD, Cao Y, Verbeek JS, . Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression. Arthritis Rheum. 2005; 52 5: 1612–1619.
   Google Scholar
• Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, . FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 2002; 16 3: 391–402.
   PubMed Web of Science ®Google Scholar
• van Lent PL, Nabbe K, Blom AB, . Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol. 2001; 159 6: 2309–2320.
   Google Scholar
• Diaz de Stahl T, Andren M, Martinsson P, . Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol. 2002; 32 10: 2915–2922.
   Google Scholar